Trial Profile
A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 23 Jan 2024 Planned End Date changed from 1 Feb 2024 to 1 Dec 2025.
- 23 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 15 Jun 2023 Planned End Date changed from 1 Apr 2023 to 1 Feb 2024.